Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albendazole + ivermectin is a combination of two antiparasitic medicines used primarily to treat various worm infections. Albendazole works by preventing worms from absorbing glucose, depleting their energy levels and leading to immobilization. Ivermectin acts on the parasite's nervous and muscular systems, causing paralysis. When administered together, these drugs work synergistically to immobilize and kill parasites more effectively than either drug alone. The combination is particularly effective against soil-transmitted helminth infections and lymphatic filariasis. It's available in various formulations, including orodispersible tablets that dissolve rapidly on the tongue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albendazole + ivermectin.